5-Minute Journal Club — ASH 2010 Presentations


Please click each issue for edition topic links.

ASH Highlights: MDS 2011 — The Future Ain't What It Used to Be
Issue 8 — March 29, 2011 — Current Edition

Go directly to our slides and commentary on:

Phase I Study of Extended Treatment Schedules of Oral Azacitidine for Patients with MDS, CMML or AML

Azacitidine for Secondary MDS and as a Bridging Option for Patients with MDS/CMML Before Allogeneic Transplant

Single-Agent Lenalidomide as Initial Induction and Postremission Therapy for Older Patients with Del(5q) Acute Myeloid Leukemia (AML)

Lenalidomide and Intensive Chemotherapy for Patients with Higher-Risk MDS or AML with Del(5q)

Novel Strategies Incorporating Arsenic Trioxide into the Initial Treatment of Acute Promyelocytic Leukemia (APL)

ASH Highlights: The Continued Impact of Proteasome Inhibitors and IMiDs in Multiple Myeloma Issue 7 — March 16, 2011

Go directly to our slides and commentary on:

Subcutaneous versus Intravenous Administration of Bortezomib in Multiple Myeloma

Pomalidomide/Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma

Carfilzomib as a Single Agent in Relapsed/Refractory Multiple Myeloma

ASH Highlights: Mantle-Cell Blues
Issue 6 — March 7, 2011

Go directly to our slides and commentary on:

High-Dose Ara-C with R-CHOP and Autologous Stem Cell Transplant (ASCT) in Mantle-Cell Lymphoma

Lenalidomide/Dexamethasone as Salvage Treatment in Mantle-Cell Lymphoma (MCL)

R-CHOP-21 Followed by I-131 Tositumomab Consolidation in Diffuse Large B-Cell Lymphoma (DLBCL)

R-CHOP-14 Followed by ICE Consolidation without Radiation Therapy for Primary Mediastinal B-Cell Lymphoma (PMBCL)

An Avalanche of Data in an Uncommon Set of Diseases: 5 ASH Papers on T-Cell Lymphomas Issue 5 — February 22, 2011

Go directly to our slides and commentary on:

Activity and Safety of Pralatrexate and Romidepsin in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

Activity and Safety of Brentuximab Vedotin (SGN-35) in Relapsed/Refractory Systemic Anaplastic Large Cell Lymphoma (sALCL)

Activity of Denileukin Diftitox and Pralatrexate in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)

ASH Shocker: Brentuximab Vedotin in Advanced Refractory Hodgkin Lymphoma
Issue 4 — February 11, 2011

Go directly to our slides and commentary on:

Brentuximab in Relapsed/Refractory Hodgkin Lymphoma

ABVD versus Stanford V in Hodgkin Lymphoma

PET Scans in Hodgkin Lymphoma

The Exciting New CML Maze
Issue 3 — February 2, 2011

Go directly to our slides and commentary on:

Nilotinib in the Early Management of Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

Dasatinib in the Initial Management of Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

Systematic Review and Meta-Analysis of the Relative Efficacy of Treatments for Chronic Myeloid Leukemia (CML)

Bosutinib versus Imatinib in the Initial Management of Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

Rituximab versus Watch and Wait in Follicular Lymphoma... and More
Issue 2 — January 21, 2011

Go directly to our slides and commentary on:

Rituximab versus Watch and Wait in the Management of Previously Untreated Asymptomatic Nonbulky Follicular Lymphoma

Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL)

Incidence of Therapy-Related Myeloid Neoplasia Among Patients with Chronic Lymphocytic Leukemia (CLL) After Fludarabine/Cyclophosphamide (FC) versus Single-Agent Fludarabine (F) as Initial Treatment

Bortezomib/Rituximab Combination in the Management of Relapsed Follicular Lymphoma

ASH Highlights: Treatment of Multiple Myeloma Continues to Storm Forward
Issue 1 — January 11, 2011

Go directly to our slides and commentary on:

Carfilzomib/Lenalidomide/Dexamethasone (CRd) as Initial Therapy for Patients with Newly Diagnosed Multiple Myeloma (MM)

Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (MM) or MM in the Post-Transplant Setting

Bortezomib-Based Maintenance Therapy for Elderly Patients with Newly Diagnosed Multiple Myeloma (MM)

Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM)